Voyager's results last week were only for Phase 1 and look at the company's market cap. No reason why, once AMBS's huge financial mess is settled and someone can move MANF forward (granted it will take a lot of $$$), MANF couldn't be yielding Phase I results in the not too far off future (across Parkinson's or retinitis pigmentosa). Meanwhile, our market cap is 2-3 million and Voyager's is 400 million.
(4)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links